CCA
QNCX icon

Catalyst Capital Advisors’s Quince Therapeutics QNCX Stock Holding History

Catalyst Capital Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed -$14K – 465
2019
Q2 		$14K Buy
+2
New +$11.9K ﹤0.01% 292

Other funds holding QNCX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's QNCX Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Quince Therapeutics (QNCX) in Q3 2019, closing a stake of 2 shares — an estimated $14K sold.

Catalyst Capital Advisors first reported a position in QNCX in Q2 2019 and held it in 1 quarter. The position peaked at $14K in Q2 2019. 39 funds tracked by Wall St. Rank hold QNCX as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Quince Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2 Quince Therapeutics shares in Q3 2019, an estimated $14K.
  • Catalyst Capital Advisors first reported a position in Quince Therapeutics in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Quince Therapeutics position peaked at $14K in Q2 2019.
  • 39 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.